skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: All three of these companies were once market darlings that have fallen from their more favorable market days and are now attempting turnarounds. Do any of these companies appear to be a turnaround buy at their current levels? If not,and if they sit in one's portfolio, should they be ejected? if so, how would they rate from worst (eject 1st)to best (still hope, eject last).
Thanks!
Read Answer Asked by WAYNE on May 09, 2017
Q: CHH has issued a press release of their signing a New 5-year Credit Facilities for Completion of Debt Refinancing Plan. The reduction in borrowing costs from $26.4M in 2015 to a pro-forma of $4.5M along with a reduction in their weighted average interest rate from 6.7% to 5.25% is impressive. Would you please provide your assessment of this company and also comment if it time to buy this stock? Thanks Gordon
Read Answer Asked by Gordon on May 05, 2017
Q: Goodday folks..Just a huge thank you for getting on the straight and narrow. Question is bought 2850 shares of sis at 8.20 . Should I sell 1000 shares and Buy What.. No Energy have plenty.. Thanks for everything Respectfully Cliff
Read Answer Asked by cliff on May 04, 2017
Q: Savaria used up there cash finally making an acquisition this week on Span-America Medical Systems.
Do you think Savaria will continue to make adjustments?
Savaria is up 37% in last 3 months. Do you think the Dividend will increase?
Do you still see Growth Potential?
Nice call since 6 on Savaria.
Keep up the Great work Team 5i!
Thanks. Barry.
Read Answer Asked by Barry on May 04, 2017
Q: I am looking for a health care ETF. Right now I am looking at ZHU and XHC. One is global and one is US focused.
ZUH has a MER of 0.39 and a yield of 0.42.
While XHC has a MER of 0.65 but a yield of 1.49.Which I think cancels out the higher MER.

I am not sure which one is right for me or how to choose. Could I use growth potential? Does one have more growth potential than the other? Or what other factors could I use to help me decide?
Read Answer Asked by David on May 01, 2017
Q: Good day

I will like your assistance on guiding my investment decision. I have read your report on Knight Therapeutics. After Knight has deployed its war chest($736,000,000), you are forecasting earnings per share of $0.59, plus the EPS for the last quarterly report of 0.06$. If earnings grow at 15% per year for the next 5 years, then in 2022, EPS will be :

2017 2018 2019 2020 2021 2022

$0.65 $0.75 $0.86 $0.99 $1.14 $1.31

I am assuming cash is deployed this year, the share count remains constant and investors in 2022 are willing to pay 15 times EPS. If this scenario holds, then in 2022, the share price should trade at around $20 (1.31 X 15). At current price ($10.60), this scenario would result in an annual rate of return for the next five years of 13.1%. Are you comfortable with my scenario or would you change some of my parameters ?

Gilles
Read Answer Asked by Gilles on May 01, 2017